By Audrey Landers, Intern
For those in the medical community, autumn brings endless sniffles, coughs and most importantly, the annual influenza season. Since 2010, the Center for Disease Control & Prevention (CDC) has recommended that Americans 6 months and older receive the influenza vaccine in order to control the spread of the disease. Suppliers began shipping out vaccines for the 2017-2018 influenza season in September.
Recommended 2017-2018 Vaccines
Vaccines for the 2017-2018 flu season will be available in the forms of a needle injection, a jet injection and an intranasal spray. These include the Inactivated Influenza Vaccines (IIVs) as well as Recombinant Influenza Vaccines (RIVs) in both trivalent and quadrivalent formulas. For this coming flu season, the CDC has recommended only the injectable influenza vaccines with the following options:
- Standard dose injections
- High dose injections
- Injections made with adjuvant
- Injections made with virus grown in cell culture
- Injections made with vaccine production technology that does not require the flu virus
All of the flu vaccines licensed in the United States for the 2017-2018 season will contain the following influenza strains:
- An A/Michigan/45/2015(H1N1)pdm09-like virus
- An A/Hong Kong/4801/2014(H3N2)-like virus
- A B/Brisbane/60/2008-like virus
- A B/Phuket/3073/2013-like virus (quadrivalent only)
No single recommended vaccine is preferred over the others. If you have more than one vaccine type available, you may use your own discretion to select what is appropriate for each patient.
Due to its ineffectiveness during the 2013-2014 and 2015-2016 flu seasons, intranasal sprays, also known as Live Attenuated Influenza Vaccines (LAIV4), are not recommended for the coming 2017-2018 flu season. Currently the only LAIV4 vaccine on the market is FluMist Quadrivalent, produced by MedImmune. If your practice has access to this vaccine, note that it is not recommended by the CDC.
Quality Reporting with MIPS #110: Preventative Care and Screening- Influenza Immunization
MIPS #110: Preventative care and Screening- Influenza Immunization is the percentage of patients aged 6 months and older seen for an in office visit between January 1 and March 31 AND October 1 and December 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization.
| Office Visit
|| Quality Data Code
|| Service Provided
| January 1, 2017 - March 31, 2017
October 1, 2017 - December 31, 2017
An influenza immunization is administered to the patient during the months of August through December or 2016 or January through March of 2017.
An influenza immunization was not administered for reasons documented by the clinician.
An influenza immunization was not administered with no reason documented.
For more information, you can view the entire measure here.
Due to the difficulty some physicians may face in reporting this measure twice in one year, SCG Health strongly recommends that this measure be reported through electronic clinical quality measures (eCQM) using CMS measure ID CMS 147v6. The eCQM version only requires the measure be reported for one flu season during the calendar year.